Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health
  • National Cancer Institute (P30 CA008748, K08CA282987)

This publication has 41 references indexed in Scilit: